Importance of Premarket Labeling and Packaging Safety Evaluations in Minimizing Postmarket Medication Errors
Medication errors reported by healthcare practitioners to the ISMP National Medication Errors Reporting Program (ISMP MERP) demonstrate the need for the pharmaceutical industry to be more proactive in identifying error-prone characteristics of drug product labeling and packaging. Much progress has been made in advancing premarket safety testing of medication brand names. However, in comparison, not enough is being done to assure that safety evaluations of proposed labeling and packaging are being conducted prior to product launch. Look-alike products and misleading container labeling represent more than 25% of the error reports submitted to ISMP. This free program will utilize case examples and product images to illustrate common safety issues that lead to dispensing and administration errors made in community pharmacies and hospitals, as well as in the home.
Webinar Recording
Supporting Materials
Learning Objectives
-
Identify common container labeling pitfalls that lead to medication errors
-
Understand the importance of labeling and packaging safety evaluations in the premarket phase
-
Identify relevant USP standards, FDA guidance, and ISMP recommendations to prevent medication errors
Speakers
Michael R. Cohen, RPh, MS, ScD (hon.), DPS (hon.), FASHP, President, ISMP
Rebecca Lamis, PharmD, FISMP, Manager, Medication Safety Board
CE Accreditation
No continuing education credits are available for this activity.
This activity is funded by Novartis Name Creation and Regulatory Strategy.
